These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 2732121)

  • 1. The pharmacokinetics of aztreonam and penetration into the bronchial secretions of critically ill patients.
    Boccazzi A; Langer M; Mandelli M; Ranzi AM; Urso R
    J Antimicrob Chemother; 1989 Mar; 23(3):401-7. PubMed ID: 2732121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Penetration of ceftazidime into bronchial secretions in critically ill patients.
    Langer M; Cantoni P; Bellosta C; Boccazzi A
    J Antimicrob Chemother; 1991 Dec; 28(6):925-32. PubMed ID: 1816189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of aztreonam in lower respiratory tract infections.
    Cook JL
    Urology; 1988 Jun; 31(6 Suppl):33-6. PubMed ID: 3287748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of aztreonam and imipenem in critically ill patients with pneumonia.
    McKindley DS; Boucher BA; Hess MM; Croce MA; Fabian TC
    Pharmacotherapy; 1996; 16(5):924-31. PubMed ID: 8888088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Summary of worldwide clinical trials of aztreonam in patients with lower respiratory tract infections.
    Swabb EA; Cone CO; Muir JG
    Rev Infect Dis; 1985; 7 Suppl 4():S675-8. PubMed ID: 3909323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Penetration of ciprofloxacin into bronchial secretions.
    Bergogne-Bérézin E; Berthelot G; Even P; Stern M; Reynaud P
    Eur J Clin Microbiol; 1986 Apr; 5(2):197-200. PubMed ID: 2941280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Penetration of aztreonam into human bronchial secretions.
    Bechard DL; Hawkins SS; Dhruv R; Friedhoff LT
    Antimicrob Agents Chemother; 1985 Feb; 27(2):263-4. PubMed ID: 4039120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Penetration of ampicillin into human bronchial secretions.
    Bergogne-Berezin E; Berthelot G; Kafe H; Morel C
    Infection; 1979; 7 Suppl 5():S463-4. PubMed ID: 511358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The penetration of macrolides into bronchial secretions.
    Pierre J; Bergogne-Berezin E; Kafe H; Dournovo P
    J Antimicrob Chemother; 1985 Jul; 16 Suppl A():217-20. PubMed ID: 4055550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetics of moxifloxacin in plasma and bronchial secretions in patients with severe bronchopneumonia.
    Simon N; Sampol E; Albanese J; Martin C; Arvis P; Urien S; Lacarelle B; Bruguerolle B
    Clin Pharmacol Ther; 2003 Oct; 74(4):353-63. PubMed ID: 14534522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Aztreonam: monocenter microbiological study with prevention experience in surgery].
    Malcangi A; Pesce S; Vitale M; Martinetto P
    G Batteriol Virol Immunol; 1987; 80(1-12):237-51. PubMed ID: 3509031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Penetration of cefotaxime into bronchial secretions.
    Bergogne-Berezin E; Morel C; Pierre J; Monrocq N; Dournovo P; Benard Y
    Rev Infect Dis; 1982; 4 Suppl():S392-5. PubMed ID: 6294788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of aztreonam in critically ill surgical patients.
    Cornwell EE; Belzberg H; Berne TV; Gill MA; Theodorou D; Kern JW; Yu W; Asensio J; Demetriades D
    Am J Health Syst Pharm; 1997 Mar; 54(5):537-40. PubMed ID: 9066861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and pharmacodynamics of aztreonam administered by continuous intravenous infusion.
    Burgess DS; Summers KK; Hardin TC
    Clin Ther; 1999 Nov; 21(11):1882-9. PubMed ID: 10890260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical pharmacokinetics of aztreonam. An update.
    Mattie H
    Clin Pharmacokinet; 1994 Feb; 26(2):99-106. PubMed ID: 8162661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical study of aztreonam on respiratory tract infections caused by gram-negative pathogens].
    Shimokata K; Totani Y; Morishita M; Hashigami H; Yamamoto M; Suetsugu S; Tanaka A; Umeda H; Sakai S; Kobayashi T
    Jpn J Antibiot; 1985 Nov; 38(11):3415-33. PubMed ID: 3912526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined aztreonam and gentamicin therapy for pseudomonal lower respiratory tract infections.
    Andrews R; Fasoli R; Scoggins WG; Algozzine GJ; Spann RW; Sundaresh KV; Mathers JA; Babb R; Kuppinger M; Cooper B
    Clin Ther; 1994; 16(2):236-52. PubMed ID: 8062319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of aztreonam in infected patients.
    Mattie H; Matze-van der Lans A
    J Antimicrob Chemother; 1986 Feb; 17(2):215-9. PubMed ID: 3700287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Penetration of ciprofloxacin in bronchial secretions after intravenous administration.
    Berré J; Thys JP; Husson M; Gangji D; Klastersky J
    J Antimicrob Chemother; 1988 Oct; 22(4):499-504. PubMed ID: 3204076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of empiric aztreonam and aminoglycoside regimens in the treatment of serious gram-negative lower respiratory infections.
    Bjornson HS; Ramirez-Ronda C; Saavedra S; Rivera-Vázquez CR; Liu C; Hinthorn DR
    Clin Ther; 1993; 15(1):65-78. PubMed ID: 8458056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.